AzTrials
AzTrials

Crohn DiseaseNCT03481751

Validation and Interobserver Reliability of a Simple Ultrasound Score for Crohn's Disease

An observational study of Crohn Disease and Ultrasound, run by Haukeland University Hospital at 3 sites in Norway.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Crohn's disease (CD) is a chronic inflammatory disease in the gastrointestinal (GI) tract. It is characterized by an alternating course between remission and relapse, which necessitates subsequent adjustments in medical therapy. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Crohn Disease, Ultrasound
What is being tested?
Diagnostic test: Ultrasound
How many people
124 participants
Where
3 sitesNorway
Study dates
8 Jan 2018to 20 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with Crohn's disease scheduled for assessment with ileocolonoscopy is considered as eligible, thus, the study population is heterogeneous. The ultrasonographic scoring system will be tested at different intestinal locations and disease activities, and consequently, a heterogeneous population is thus suitable.

Who may be able to join

  • Patient with Crohn's Disease scheduled for ileocolonoscopy.

Who cannot join

  • <18 years
  • >75 years
  • CD located in other areas than the terminal ileum or colon
  • pregnancy
  • chronic obstructive lung disease
  • acute coronary heart disease
Show all 10Show fewer
  • clinically unstable heart disease
  • ongoing gastroenteritis
  • presence of an intra-abdominal abscess or a fistula
  • obesity (BMI>30 kg/m2)

Trial locations and contacts

3 sites in 1 country.

Norway3 sites
  • Ålesund Hospital

    Ålesund, Møre og Romsdal

  • Department of Medicine, Haukeland University Hospital

    Bergen, Hordaland, 5021

  • University Hospital of North Norway Tromsø

    Tromsø, Troms

Other trials in Norway

About this study

Official title: Validation and Interobserver Reliability of an Ultrasonographic Score for the Assessment of Disease Activity in Crohn's Disease

Crohn's disease (CD) is a chronic inflammatory disease in the gastrointestinal (GI) tract. It is characterized by an alternating course between remission and relapse, which necessitates subsequent adjustments in medical therapy. Thus, it is important to have suitable tools to assess disease activity, and currently the reference standard is using ileocolonoscopy. However, ileocolonoscopy causes major patient discomfort and due to logistic reasons, it cannot be performed on a regular basis. High frequency ultrasound (US) is a potentially useful tool to evaluate changes in disease activity in affected bowel segments. Although there are some studies using US in CD patients to construct ultrasonographic scoring systems, there are no validated scores in daily clinical practice. In a recent study by Nylund et al, we used multiple linear regression to select which simple conventional ultrasound parameters that should be included in an ultrasound scoring system (Simple Ultrasound Score of Crohn's Disease (SUS-CD)) using endoscopy as a reference (unpublished data). In this study, we aim to validate this scoring system using an endoscopic score (Simple endoscopic activity score for Crohn's disease (SES-CD)) as reference standard and to assess interobserver variability.

The scoring system might be a useful supplement to endoscopy to follow up CD patients.

Read the detailed description

Although there are some studies where they used conventional ultrasound and contrast enhanced ultrasound (CEUS) on CD patients to construct ultrasonographic scoring systems, there is currently no validated scores used in daily clinical practice. Even though CEUS provides potentially useful information, the method requires extensive sonographic training, high-end scanners and is time-consuming, making this technique less suitable in daily life. In contrast, conventional ultrasound can be performed using portable ultrasound system and requires less training. Furthermore, evidence suggests that bowel wall thickness predicts endoscopic remission better than CEUS. Thus, conventional ultrasound should be used to construct an ultrasonographic scoring system.

In a recent study, we used multiple linear regression to select which simple conventional ultrasound parameters that should be included in an ultrasound scoring system (Simple Ultrasound Score of Crohn's Disease (SUS-CD)) using endoscopy as a reference. In this study, the primary objective is to validate the SUS-CD scoring system using a validated endoscopic score (Simple endoscopic activity score for Crohn's disease (SES-CD)) as reference standard and further to assess interobserver variability. Secondary objectives are to assess if changes in the SUS-CD score correlate to clinical and biochemical disease activity parameters used in CD, and to examine if SUS-CD could be used to predict treatment effect.

Intervention:

All patients will be examined with trans-abdominal ultrasound and ileocolonoscopy, and relevant blood and faeces samples will be collected.

Ultrasound:

The ultrasound examinations will be performed with a mid to high range ultrasound scanner equipped with a curvilinear abdominal probe and a high frequency probe. Frequency, focus and gain settings are optimised to get the best images of the patient. First, a curvilinear probe providing good depth penetration is used to get overview and to identify gross pathology. Next, a detailed examination of the large bowel is performed by scanning systematically from the terminal ileum and further distally, using a linear probe with high frequency. The colon is examined in both longitudinal and transverse views. The rectum is examined using the curvilinear probe because the bowel-segment is deeply located. The sonographic examination is scored according to the SUS-CD. Still images and cine loops in each segment are stored and the locations are identified using external markers obtained from the US-machine. The examiner is blinded to the findings on ileocolonoscopy and biochemical parameters when performing the ultrasound examinations.

Color Doppler can be used to evaluate bowel wall vascularity. All bowel segments are scanned with color-coded Doppler sonography using standardized settings and velocity scale and wall filter adjusted to the lowest settings, enabling registration of lower velocities in the intestinal wall. The data is saved as a cine loop, and the color-Doppler scores are registered in SUS-CD.

Main study parameter:

Conventional ultrasonographic parameters in SUS-CD: bowel wall thickness, stratification, colour Doppler, fatty wrapping.

Other parameters: Endoscopic disease activity score (SES-CD), blood and faecal inflammatory parameters, clinical disease activity (Harvey Bradshaw Index).

Interobserver reliability:

All patients included at Haukeland University Hospital are scanned by two observers to assess interobserver reliability. None of the observers are aware of the SES-CD, however, the Montreal classification is known.

Being tested
Diagnostic test: Ultrasound
Keywords
Crohn Disease, Ultrasound, Monitoring, Disease activity
Medical subject headings
Crohn Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Diagnostic test: UltrasoundDiagnostic test

    Transabdominal ultrasound of the bowel for categorization of disease activity

Study groups in NCT03481751
Study groupRoleWhat they receive
Patients with Crohn DiseasePatients with Crohn's disease scheduled for ileocolonoscopy
Receives: Diagnostic Test: Diagnostic test: Ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Remission

    The primary outcome measure is clinical and biochemical remission at 12 months (defined as Simple index <5, Calprotectin<250, C reactive protein (CRP)<5 and no steroids). For patients examined with ileocolonoscopy as part of regular follow up after 8-16 months the end-point will be mucosal healing (defined as SES-CD 0-2).

    Measured: Follow up period (12 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2018
  2. Study start8 Jan 2018
  3. Primary completion20 Dec 2020
  4. Study completion20 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
124 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03481751
Sponsor's protocol ID
2017/1750
Status last verified
Sep 2022
First submitted
22 Mar 2018
Last updated
4 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Saevik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease. J Crohns Colitis. 2021 Jan 13;15(1):115-124. doi: 10.1093/ecco-jcc/jjaa112.

    PubMed 32504533

Questions about this trial

What is this clinical trial studying?

An observational study of Crohn Disease and Ultrasound, run by Haukeland University Hospital at 3 sites in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Remission (time frame: Follow up period (12 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03481751, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in